Literature DB >> 303529

High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement.

A T Skarin, K S Zuckerman, S W Pitman, D S Rosenthal, W Moloney, E Frei, G P Canellos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 303529

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  19 in total

1.  Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort.

Authors:  Julien Cobert; Ephraim Hochberg; Nina Woldenberg; Fred Hochberg
Journal:  J Neurooncol       Date:  2009-12-18       Impact factor: 4.130

Review 2.  New approaches in primary central nervous system lymphoma.

Authors:  Eleanor Fraser; Katherine Gruenberg; James L Rubenstein
Journal:  Chin Clin Oncol       Date:  2015-03

3.  Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate.

Authors:  P O Greiner; J Zittoun; J Marquet; J M Cheron
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

Review 4.  The Challenge of Primary Central Nervous System Lymphoma.

Authors:  Julia Carnevale; James L Rubenstein
Journal:  Hematol Oncol Clin North Am       Date:  2016-12       Impact factor: 3.722

Review 5.  Primary central nervous system lymphoma.

Authors:  W S Velasquez
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 6.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 7.  The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors:  C Erlichman; R C Donehower; B A Chabner
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

8.  Combination chemotherapy for advanced non-Hodgkin's lymphoma of unfavourable histology.

Authors:  T A Lister; M H Cullen; R B Brearley; M E Beard; A G Stansfeld; J M Whitehouse; P F Wrigley; J M Ford; J S Malpas; D Crowther
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

9.  The need for prophylactic treatment to the central nervous system in patients with aggressive non-Hodgkin's lymphoma.

Authors:  C J Hawkey; P J Toghill
Journal:  Postgrad Med J       Date:  1983-05       Impact factor: 2.401

10.  How I treat CNS lymphomas.

Authors:  James L Rubenstein; Neel K Gupta; Gabriel N Mannis; Amanda K Lamarre; Patrick Treseler
Journal:  Blood       Date:  2013-08-20       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.